Evidence map›Paper›PMID 35401081›Full record

ArticleFrontiers in neuroscience2022

Cerebellar Pathology in an Inducible Mouse Model of Friedreich Ataxia.

Elizabeth Mercado-Ayón, Nathan Warren, Sarah Halawani, Layne N Rodden, Lucie Ngaba, Yi Na Dong, Joshua C Chang, Carlos Fonck, Fulvio Mavilio, David R Lynch and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Aging, Neurodegenerative Disorders, and Cerebellum.International journal of molecular sciences · 2024
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Elizabeth Mercado-AyónDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Nathan WarrenDepartment of Pediatrics and Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Sarah HalawaniDepartment of Pediatrics and Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Layne N RoddenDepartment of Pediatrics and Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Lucie NgabaDepartment of Pediatrics and Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Yi Na DongDepartment of Pediatrics and Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Joshua C ChangAudentes Therapeutics, San Francisco, CA, United States.
Carlos FonckAudentes Therapeutics, San Francisco, CA, United States.
Fulvio MavilioAudentes Therapeutics, San Francisco, CA, United States.
David R LynchDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Hong LinDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Children's Hospital of Philadelphia · USUniversity of Pennsylvania · USUniversity of Modena and Reggio Emilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by deficiency of the mitochondrial protein frataxin. Lack of frataxin causes neuronal loss in various areas of the CNS and PNS. In particular, cerebellar neuropathology in FRDA patients includes loss of large principal neurons and synaptic terminals in the dentate nucleus (DN), and previous studies have demonstrated early synaptic deficits in the Knockin-Knockout mouse model of FRDA. However, the exact correlation of frataxin deficiency with cerebellar neuropathology remains unclear. Here we report that doxycycline-induced frataxin knockdown in a mouse model of FRDA (FRDAkd) leads to synaptic cerebellar degeneration that can be partially reversed by AAV8-mediated frataxin restoration. Loss of cerebellar Purkinje neurons and large DN principal neurons are observed in the FRDAkd mouse cerebellum. Levels of the climbing fiber-specific glutamatergic synaptic marker VGLUT2 decline starting at 4 weeks after dox induction, whereas levels of the parallel fiber-specific synaptic marker VGLUT1 are reduced by 18-weeks. These findings suggest initial selective degeneration of climbing fiber synapses followed by loss of parallel fiber synapses. The GABAergic synaptic marker GAD65 progressively declined during dox induction in FRDAkd mice, while GAD67 levels remained unaltered, suggesting specific roles for frataxin in maintaining cerebellar synaptic integrity and function during adulthood. Expression of frataxin following AAV8-mediated gene transfer partially restored VGLUT1/2 levels. Taken together, our findings show that frataxin knockdown leads to cerebellar degeneration in the FRDAkd mouse model, suggesting that frataxin helps maintain cerebellar structure and function.

Indexed as

cerebellumfrataxingene therapyglutamatergic and GABAergic synapsesmitochondria dynamics

Identifiers

PMID35401081
PMCPMC8987918
OpenAlexW4220749052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.